Alan Wayne, MD
Family Medicine · Stevenson, ALNPI 1477531283
Payments from drug & device makers
Across 534 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$831
- Novartis$680
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$437
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,511100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 100 | $1,555 |
| Novo Nordisk | 98 | $1,410 |
| AbbVie(2 entities) | 70 | $1,061 |
| AstraZeneca | 48 | $831 |
| Novartis | 41 | $680 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $437 |
| Lundbeck LLC | 14 | $294 |
| SK Life Science, Inc. | 14 | $284 |
| Pfizer | 15 | $253 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $201 |
| Biohaven Pharmaceuticals, Inc. | 9 | $152 |
| Astellas Pharma US Inc | 6 | $127 |
| Amgen | 7 | $116 |
| Sumitomo Pharma America, Inc. | 4 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Lilly USA, LLC | 5 | $87 |
| UCB, Inc. | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| Boehringer Ingelheim | 4 | $61 |
| Mylan Specialty L.p. | 3 | $59 |
| Merck | 3 | $54 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 3 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Abbott | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Eisai Inc. | 2 | $25 |
| Corium, LLC | 1 | $25 |
| Optinose US, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$8,520 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 153 | $237,177 |
| OzempicSemaglutide | 147 | $178,720 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $171,554 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 157 | $130,632 |
| EliquisApixaban | 159 | $128,153 |
| IngrezzaValbenazine Tosylate | 12 | $101,207 |
| CreonLipase/Protease/Amylase | 12 | $94,926 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $93,202 |
| LinzessLinaclotide | 82 | $62,407 |
| MounjaroTirzepatide | 61 | $62,275 |
| Repatha SureclickEvolocumab | 100 | $57,954 |
| EntrestoSacubitril/Valsartan | 79 | $55,044 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,746 | $44,493 |
| VraylarCariprazine Hcl | 31 | $43,153 |
| RybelsusSemaglutide | 43 | $40,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,410 | $218,745190 claims |
| AbbVieCreon, Linzess, Vraylar | $1,061 | $200,486125 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,555 | $193,774295 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $831 | $175,703250 claims |
| PfizerEliquis, Nurtec Odt | $253 | $146,175175 claims |
| Lilly USA, LLCMounjaro | $87 | $62,27561 claims |
| NovartisEntresto | $680 | $55,04479 claims |
| Boehringer IngelheimJardiance | $61 | $33,39554 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $32,66866 claims |
| UCB, Inc.Briviact, Neupro | $81 | $29,03927 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $437 | $21,72113 claims |
| MerckJanumet Xr, Belsomra | $54 | $12,21730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Stevenson
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.